TuHURA Biosciences, Inc. (HURA)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$1.72+3.61%
Close 2026-11-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
QuarterlyIQ Insights · HURA
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
A comparable price-assumption read is not available for this company.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-11-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Worth watching into the next print: this name operates in a high-miss-rate industry and is a smaller-cap name (higher miss base rate). A fundamental tilt, not a price call.
Model as of 2026-11-04 · Compared with 66 industry peers
HURA — capital allocation — Creation of a Direct Financial Obligation or an Obligation under an Off-Balan…
Dated 2026-10-16
Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. As previously disclosed, on April 21, 2026, TuHURA Biosciences, Inc. (the “Company”) entered into a Loan Agreement (the “Loan Agreement”) with Parkview Holdings One LLC, as lender. The Loan Agreement provides for a revolving credit facility that matures on April 21, 2031, with a maximum amount of loan availability of $50 million. On October 9, 2026, the Company received and borro…
Why it matters: Cash was $1.0 million at June 30, while the company had drawn $5.7 million from its credit line by the Q2 update. More draws support trial work but add debt and interest costs.
Worry ifA later filing shows cash below $1.0 million and added borrowing. Or, it says TuHURA cannot draw enough funds for planned work.
Less concerning ifA later filing shows cash above $1.0 million without added borrowing. Or, TuHURA reports enough funds for planned work.
Why it matters: A grant would add a regulatory milestone for the lead drug. A denial or missed year-end date would remove that near-term progress marker.
Supportive ifFDA grants orphan drug status to IFx-2.0 for Merkel cell cancer by December 31, 2026.
Worry ifFDA denies the request, or TuHURA reports no grant by December 31, 2026.
Why it matters: The trial start would turn FDA feedback into a live study. A delay would push back the first planned safety and response data.
Supportive ifBy December 31, 2026, TuHURA announces it has started the Phase 1b/2 TBS-2025 trial. The trial is for mutated NPM1 relapsed or refractory AML.
Worry ifThe trial has not started by December 31, 2026, or TuHURA reports a new FDA or trial delay.
Why it matters: These results would give the first human test of TBS-2025 in this AML group. Safety issues or no responses would weaken the early study case.
Watch forBy June 30, 2027, TuHURA reports safety and response data from the TBS-2025 AML trial. There are no dose-limiting safety issues and at least one response.
Also watch forThe report shows a dose-limiting safety issue or no responses. Or, TuHURA does not report the data by June 30, 2027.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$267 on $10,000 · ±2.7% | How much price usually moves either way. |
| Bad day | $1,027 loss on $10,000 · 10.3% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $8,254 loss on $10,000 · 82.5% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.